Special Issue "MicroRNAs as Biomarkers and Therapeutic Targets in Disease"

A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Molecular Genetics and Genomics".

Deadline for manuscript submissions: 20 December 2021.

Special Issue Editor

Dr. Peixin Dong
E-Mail Website
Guest Editor
Department of Obstetrics and Gynecology, Hokkaido University, Sapporo 060, Japan
Interests: miRNA; incRNA; circRNA; gynecological cancers; metastasis; EMT; chemoresistance; cancer biomarker; therapeutic target
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), make up the majority of the human transcriptome and have been hot topics in recent years. MiRNAs are small, endogenous non-coding RNAs that bind to complementary sequences in their target mRNAs to modulate the expression of target mRNAs. LncRNAs competitively sponge miRNAs as competing endogenous RNAs through base complementarity, indirectly controlling the effects of miRNAs on their target genes. CircRNAs interact with diverse molecules (including miRNAs) to regulate gene expression and cell function. NcRNAs play crucial roles in diseases (including cancer). NcRNAs are promising biomarkers for the diagnosis, staging, classification, and prognosis of diseases, and for monitoring clinical response to therapy. Therefore, ncRNAs can be considered as novel biomarkers and therapeutic targets in diseases.

In this Special Issue, we are inviting reviews, perspectives, and original research articles focused on the functions, regulatory mechanisms, and clinical applications of all kinds of ncRNAs (especially miRNAs). We also welcome studies that highlight new technologies, new analysis platforms, new animal models, and new manipulation tools for the study of ncRNAs.

Prof. Dr. Peixin Dong
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • miRNA
  • lncRNA
  • circRNA
  • biomarker
  • therapeutic target

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis
by , , , and
Genes 2021, 12(11), 1701; https://0-doi-org.brum.beds.ac.uk/10.3390/genes12111701 - 26 Oct 2021
Viewed by 131
Abstract
Gemcitabine is the first-line treatment for patients with pancreatic cancer (PC), yet most patients develop resistance to gemcitabine. Recent studies showed that circular RNAs (circRNAs) have important regulatory roles in PC progression and chemoresistance. In this study, the ability of circRNA circ_0092367 to [...] Read more.
Gemcitabine is the first-line treatment for patients with pancreatic cancer (PC), yet most patients develop resistance to gemcitabine. Recent studies showed that circular RNAs (circRNAs) have important regulatory roles in PC progression and chemoresistance. In this study, the ability of circRNA circ_0092367 to enhance gemcitabine efficacy was tested and the underlying molecular mechanism of circ_0092367 was investigated. The expression levels of circ_0092367, miR-1206, and ESRP1 were measured using qRT-PCR experiments. The effects of circ_0092367, miR-1206, and ESRP1 on PC cell lines exposed to gemcitabine were examined by CCK-8 assays. We performed luciferase assays to determine the relationship between circ_0092367 and miR-1206 and between miR-1206 and ESRP1. We demonstrated that circ_0092367 was significantly downregulated in PC tissues and cell lines, and a high expression of circ_0092367 was associated with improved survival in patients with PC. Gain- and loss-of-function assays revealed that circ_0092367 inhibited epithelial–mesenchymal transition (EMT) phenotypes and sensitized PC cells to gemcitabine treatment in vitro and in vivo. Cytoplasmic circ_0092367 could directly repress the levels of miR-1206 and thus upregulate the expression of ESRP1, thereby inhibiting EMT and enhancing the sensitivity of PC cells to gemcitabine treatment. Our findings show that circ_0092367 plays a crucial role in sensitizing PC cells to gemcitabine by modulating the miR-1206/ESRP1 axis, highlighting its potential as a valuable therapeutic target in PC patients. Full article
(This article belongs to the Special Issue MicroRNAs as Biomarkers and Therapeutic Targets in Disease)
Back to TopTop